To evaluate the response to Glucagon during hypoglycemia
Study identifier:D1020C00018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, open, two-way Cross-over, Phase I Study to Evaluate the Response to Glucagon versus the spontaneous counter-regulatory response in T2DM Patients treated with AZD1656 and Metformin during hypoglycemia
Medical condition
Type 2 Diabetes
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD1656, Glucagon
Sex
All
Actual Enrollment
8
Study type
Interventional
Age
18 Years - 75 Years
Date
Study Start Date: 01 Feb 2009
Primary Completion Date: 01 Apr 2009
Study Completion Date: 01 Apr 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD1656 Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose Drug: Glucagon 1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8 |
| Experimental: 2 | Drug: AZD1656 Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose |
Contacts
Investigators
Principal Investigator
Klas Malmberg
AstraZeneca R&D Mölndal
